摘要
目的 了解成人哮喘患者血清25-羟维生素D3 [25（OH）D3]水平与治疗前后肺功能改善程度的相关性,为哮喘控制提供新思路.方法 收集门诊确诊中度哮喘患者95例,入组后测定血清25（OH）D3浓度,给予沙美特罗替卡松（50 μg/250 μg）,1吸/次,1次/12 h,规范治疗3个月.测定治疗前后患者基础肺功能,如第1秒用力呼气容积占预计值百分比（FEV1% pred）和呼气中段流速（FEF25%~75%）,并记录治疗前后哮喘控制测试（ACT）评分.对25（OH）D3浓度与治疗前后FEV1% pred、FEF25%~75%以及ACT评分的改善情况进行相关性分析.结果 入组患者95例,未按规定时间随访32例,未按医嘱规范治疗23例,有效随访患者40例.患者血清25（OH）D3浓度与治疗后FEV1% pred、FEF25%~75%和ACT评分的增加值均呈正相关（P＜0.01）.结论成人哮喘患者血清25（OH）D3浓度与哮喘治疗反应呈正相关.
Objective To explore the correlation between serum 25 （OH） D3 level and improvement degrees of pulmonary function before and after the treatment in adult patients with asthma. Methods 95 patients diagnosed as moderate asthma were selected. Their concentration of serum 25 （OH） D3 was detected. They received inhalation with salmeterohicasone （50 μg/250 μg） （ 1 inhalation every 12 hours）for 3 months. Their basic pulmonary functions before and after the treatment were detected, such as the percentage of the forced expiratory volume at the first second in the predicted value （FEV1% pred）and the forced vital capacity （FEF25%-75% ）. The asthma control test （ACT）scores before and after the treatment were recorded. The correlations between serum 25 （OH）D3 concentration and the improvements in FEV1% pred, FEF25%-75%, and ACT sores were analyzed. Results Among the 95 cases,32 ones did not receive the follow-up on time;23 ones did not receive the treatment according to the physician＇s order; and 40 ones received the follow-up to the end of the study. There was positive correlation between serum 25 （OH） D3 concentration and the increases of FEVt % pred, FEF25%-75% , and ACT scores （ P 〈 0. 01 ）. Conclusion There is a positive correlation between serum 25 （OH）D3 concentration and the therapeutic reaction in adult patients with asthma.
出处
《西南国防医药》
CAS
2014年第2期138-140,共3页
Medical Journal of National Defending Forces in Southwest China
